Recordati-Industria Chimica e Farmaceutica S.p.A. Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 4/6/2026)
| Balance Sheet | Total Assets | 5,252,280,000.00 | ROE | 36.55 % |
| Balance Sheet | Total Equity | 1,919,770,000.00 | ROA | 8.45 % |
| Cashflow | Capital Expenditures | -85,124,000.00 | P/FCF | 21.08 |
| Cashflow | Free Cash Flow | 511,772,992.00 | – | – |
| Cashflow | Operating Cash Flow | 596,897,000.00 | P/CF | 18.08 |
| Income | Earnings per Share (diluted) | 2.17 | Div. Yield | 2.54 % |
| Income | Net Income | 443,624,000.00 | P/E | 24.33 |
| Income | Shares Outstanding | 204,356,000.00 | P/B | 5.62 |
| Income | Total Revenue | 2,618,380,000.00 | P/S | 4.12 |
Ratios calculated on: 10/14/2026
Company Description
Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA and Pro Farma AG.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.recordati.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more